Duality Advisers’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Duality Advisers’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-881,770	Closed	-$67.2M	–	448
2019 Q3	$67.2M	Buy	881,770 +360,100	+69%	+$29.9M	3.75%	3
2019 Q2	$45.8M	Buy	+521,670	New	+$44.5M	4.02%	3
2019 Q1	–	Sell	-715,860	Closed	-$51.4M	–	281
2018 Q4	$51.4M	Buy	+715,860	New	+$57.7M	3%	4

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of Nova Scotia Toronto, Ontario, Canada $66.2B AUM 46.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Natixis Paris, France $24.8B AUM 35.22% 1-Year Est. Return

Duality Advisers's XBI Position: Q4 2019 in Review

Duality Advisers sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2019, closing a stake of 881,770 shares — an estimated $67.2M sold.

Duality Advisers first reported a position in XBI in Q4 2018 and held it in 3 quarters. The position peaked at $67.2M in Q3 2019. 474 funds tracked by Wall St. Rank hold XBI as of Q4 2019.

Duality Advisers reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2019 after selling out during the quarter.
Duality Advisers sold 881,770 State Street SPDR S&P Biotech ETF shares in Q4 2019, an estimated $67.2M.
Duality Advisers first reported a position in State Street SPDR S&P Biotech ETF in Q4 2018 and held it in 3 quarters.
Duality Advisers's State Street SPDR S&P Biotech ETF position peaked at $67.2M in Q3 2019.
474 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2019.

Based on Duality Advisers's 13F filing for Q4 2019, filed 10 Feb 2020.